TET2 mutations were most frequently detected in 91 cases, with 85.8%, 66.7%, and 34.3% of AITL, nTFHL other than AITL, and PTCL-NOS, respectively (AITL vs. PTCL-NOS, adjusted P value 1.56 × 10−7; Figs. 1, S5, S6, and S7). This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.